p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma

✍ Scribed by George Xinarianos; Triantafillos Liloglou; Wendy Prime; George Sourvinos; Andreas Karachristos; John R. Gosney; Demetrios A. Spandidos; John K. Field

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: French
• Weight: 855 KB
• Volume: 101
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.10598

✦ Synopsis

We examined the p53 status of 108 NSCLCs compared to the expression of MLH1 and MSH2 proteins. p53 overexpression was demonstrated by IHC in 64% of patients examined, whereas p53 mutations were detected in 43%. Twenty-two percent of mutations were located outside of the hot-spot (exons 5-8) area. p53 mutations and overexpression were more frequent in SCCL (57% and 73%, respectively) than in lung adenocarcinomas (22% and 50%, respectively). In NSCLC-carrying wild-type p53, increased expression of MSH2 correlated with p53 overexpression (p = 0.018). In addition, in SCCL, p53 mutations correlated with reduced MSH2 expression (p = 0.019). These data suggest a relationship between p53 and MSH2. While there is evidence for p53 being a transcriptional activator of MSH2, the hypothesis that MSH2 acts as a DNA-damage signaller triggering p53 overexpression needs to be clarified in future studies.